Selective Pituitary Resistance to Thyroid Hormone: Clinical Hyperthyroidism with High TSH on Levothyroxine Administration in I-131 Ablated “Graves Disease”
Resistance to Thyroid Hormone (RTH) is a rare form of hormone resistance secondary to changes in the genes encoding thyroid hormone receptors. The two subtypes, Pituitary RTH (PRTH) and Generalized RTH (GRTH), cause clinically distinguishable patient presentations. In PRTH, typically only the pituitary gland is resistant to thyroid hormone (TH) while the rest of the body maintains sensitivity. Selective pituitary resistance to thyroid hormone results in dysregulation of thyroid hormone homeostasis with clinical presentation as either euthyroid or hyperthyroidism. PRTH is characterized by elevated thyroid hormone levels with an elevated or inappropriately normal TSH concentration. Herein we describe a case report of a 70-year-old woman who complained of weight loss of over 35 lbs., palpitations, jitters, hair loss, diarrhea, fatigue, muscle weakness, etc. over 6 months, thus, indicating the presence of iatrogenic hyperthyroidism while receiving levothyroxine 175 ug daily prescribed by her primary care provider because of a reported history of “Graves disease” treated by radioactive iodine ablation of the thyroid several years ago. The daily dose of levothyroxine had been increased gradually at an interval of 3 months over a year because of persistent elevation of serum TSH level. Laboratory tests revealed markedly elevated Free T4, Free T3 and TSH levels, along with low concentrations of all lipid fractions, serum creatinine and urea nitrogen levels, indicating TSH induced hyperthyroidism or PRTH. Further testing documented a mutation of thyroid hormone receptor beta gene 2 confirming presence of PRTH. We believe that the initial diagnosis of Graves Disease was erroneous and I-131 ablation further confounded and missed the diagnosis of PRTH. Thus, the purpose of this report is to report a patient with PRTH and describe potential pitfalls in diagnosis and management of this rare disorder.
References
[1]
Refetoff, S., Dewind, L. and DeGroot, L. (1967) Familial Syndrome Combining Deaf-Mutism, Stippled Epiphyses, Goiter and Abnormally High PBI: Possible Target Organ Refractoriness to Thyroid Hormone. The Journal of Clinical Endocrinology & Metabolism, 27, 279-294. https://doi.org/10.1210/jcem-27-2-279
[2]
Refetoff, S. (1982) Syndromes of Thyroid Hormone Resistance. American Journal of Physiology, 243, E88-E98. https://doi.org/10.1152/ajpendo.1982.243.2.E88
[3]
Aritaki, S., Shimazaki, T., Ogihara, M., et al. (1989) Syndrome of Generalized (Peripheral Tissue and Pituitary) Resistance to Thyroid Hormone. Acta Paediatrica Japonica, 31, 712-720. https://doi.org/10.1111/j.1442-200X.1989.tb01385.x
[4]
McDermott, M.T. and Ridgway, E.C. (1993) Thyroid Hormone Resistance Syndromes. The American Journal of Medicine, 94, 424-432. https://doi.org/10.1016/0002-9343(93)90155-I
[5]
Salmerón De Diego, J., Rodriguez, C.A., et al. (1987) Syndrome of “Inappropriate Secretion of Thyroid-Stimulating Hormone” by Partial Target Organ Resistance to Thyroid Hormones. Acta Endocrinologica (Copenhagen), 97, 361-368. https://doi.org/10.1530/acta.0.0970361
[6]
Beck-Peccoz, P., Persani, L., Calebiro, D., et al. (2006) Syndromes of Hormone Resistance in the Hypothalamic-Pituitary-Thyroid Axis. Best Practice & Research Clinical Endocrinology & Metabolism, 20, 529-546. https://doi.org/10.1016/j.beem.2006.11.001
[7]
Persani, L. and Campi, I. (2019) Syndromes of Resistance to Thyroid Hormone Action. In: Igaz, P. and Patócs, A., Eds., Genetics of Endocrine Diseases and Syndromes, Springer, Berlin, 55-84. https://doi.org/10.1007/978-3-030-25905-1_5
[8]
Safer, J.D., O’Connor, M.G., Colan, S.D., et al. (1999) The Thyroid Hormone Receptor-Beta Gene Mutation R383H Is Associated with Isolated Central Resistance to Thyroid Hormone. The Journal of Clinical Endocrinology & Metabolism, 84, 3099-3109. https://doi.org/10.1210/jc.84.9.3099
[9]
Wan, W., Farboud, B. and Privalsky, M.L. (2005) Pituitary Resistance to Thyroid Hormone Syndrome Is Associated with T3 Receptor Mutants That Selectively Impair Beta2 Isoform Function. Molecular Endocrinology, 19, 1529-1542. https://doi.org/10.1210/me.2005-0014
[10]
Olateju, T.O. and Vanderpump, M.P.J. (2006) Thyroid Hormone Resistance. Annals of Clinical Biochemistry, 43, 431-440. https://doi.org/10.1258/000456306778904678
[11]
Narumi, S., Cho, H., Tamada, I., et al. (2010) One Novel and Two Recurrent THRB Mutations Associated with Resistance to Thyroid Hormone: Structure-Based Computational Mutation Prediction. Clinical Pediatric Endocrinology, 19, 91-99. https://doi.org/10.1297/cpe.19.91
[12]
Lee, S., Young, B.M., Wan, W., et al. (2011) A Mechanism for Pituitary-Resistance to Thyroid Hormone (PRTH) Syndrome: A Loss in Cooperative Coactivator Contacts by Thyroid Hormone Receptor (TR) Beta2 Molecular Endocrinology, 25, 1111-1125. https://doi.org/10.1210/me.2010-0448
[13]
van Gucht, A.L.M., Moran, C., Meima, M., et al. (2017) Resistance to Thyroid Hormone Due to Heterozygous Mutations in Thyroid Hormone Receptor Alpha. Current Topics in Developmental Biology, 125, 337-355. https://doi.org/10.1016/bs.ctdb.2017.02.001
[14]
Pappa, T. and Refetoff, S. (2021) Resistance to Thyroid Hormone Beta: A Focused Review. Frontiers in Endocrinology (Lausanne), 12, Article ID: 656551. https://doi.org/10.3389/fendo.2021.656551
[15]
Bantle, J.P., Seeling, S., Mariash, C.N., Ulstrom, R.A. and Oppenheimer, J.H. (1982) Resistance to Thyroid Hormones. A Disorder Frequently Confused with Graves’ Disease. Archives of Internal Medicine, 142, 1867-1871. https://doi.org/10.1001/archinte.142.10.1867
[16]
Sivakumar, T. and Chaidarun, S. (2010) Resistance to Thyroid Hormone in a Patient with Coexisting Graves’ Disease. Thyroid, 20, 213-216. https://doi.org/10.1089/thy.2009.0175
[17]
Sun, H., Xu, S., Xie, S., et al. (2017) Graves’ Disease Coexisting with Resistance to Thyroid Hormone: A Rare Case. Clinical Case Reports, 6, 337-341. https://doi.org/10.1002/ccr3.1344
[18]
Akahori, H. and Usuda, R. (2021) Graves’ Disease Coexisted with Resistance to Thyroid Hormone: A Case Report. Journal of Medical Case Reports, 15, Article No. 473. https://doi.org/10.1186/s13256-021-03061-4
[19]
Brent, G.A. (2012) Mechanisms of Thyroid Hormone Action. Journal of Clinical Investigation, 122, 3035-3043. https://doi.org/10.1172/JCI60047
[20]
Mendoza, A. and Hollenberg, A.N. (2017) New Insights into Thyroid Hormone Action. Pharmacology & Therapeutics, 173, 135-145. https://doi.org/10.1016/j.pharmthera.2017.02.012
[21]
Groeneweg, S., Peeters, R.P., Visser, T.J. and Visser, W.E. (2017) Therapeutic Applications of Thyroid Hormone Analogues in Resistance to Thyroid Hormone (RTH) Syndromes. Molecular and Cellular Endocrinology, 458, 82-90. https://doi.org/10.1016/j.mce.2017.02.029
Maruo, Y., Mori, A., Morioka, Y., et al. (2016) Successful Every-Other-Day Liothyronine Therapy for Severe Resistance to Thyroid Hormone Beta with a Novel THRB Mutation, Case Report. BMC Endocrine Disorders, 16, Article No. 1. https://doi.org/10.1186/s12902-015-0081-7
[24]
Anzai, R., Adachi, M., Sho, N., et al. (2012) Resistance to Thyroid Hormone Beta: A Focused Review. Long-Term 3,5,3’-Triiodothyroacetic Acid Therapy in a Child with Hyperthyroidism Caused by Thyroid Hormone Resistance: Pharmacological Study and Therapeutic Recommendations. Thyroid, 22, 1069-1075. https://doi.org/10.1089/thy.2011.0450
